Pharmaceutical - Arena Pharmaceuticals, Markets & Marketing

Filter

Popular Filters

Eisai to double Belviq sales force by December

Eisai to double Belviq sales force by December

15-10-2013

Eisai’s US subsidiary will increase its force for the obesity drug Belviq to around 400 representatives…

Arena PharmaceuticalsBelviqEisaiManagementMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Eisai's launch plan for obesity drug Belviq in USA enters consumer phase

16-09-2013

The US launch campaign by Japanese drug major Eisai (TYO: 4523) of the weight-loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

It's official: "obesity is a disease," says AMA

20-06-2013

The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Arena/Eisai's Belviq at last to launch in the USA

07-06-2013

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) says that its long-awaited weight loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Arena Pharma links with Ildong for Belviq marketing in South Korea

08-11-2012

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) has entered into a marketing and supply agreement with…

Arena PharmaceuticalsAsia-PacificBelviqIldong PharmaLicensingMarkets & MarketingMetabolicsPharmaceutical

Vivus' Qsymia set to be most widely used emerging therapy for obesity treatment

26-07-2012

Novel emerging agents will experience rapid uptake owing to the high prevalence of obese or overweight…

Arena PharmaceuticalsBelviqMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top